Evidence map›Paper›PMID 38020730›Full record

ArticleClinical & translational immunology2023

Improving thymus implantation for congenital athymia with interleukin-7.

Hyunjung Min, Laura A Valente, Li Xu, Shane M O'Neil, Lauren R Begg, Joanne Kurtzberg, Anthony J Filiano

Open access · goldAbstract read
In one paragraph

Article in Clinical & translational immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Advances in IL-7 Research on Tumour Therapy.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hyunjung MinMarcus Center for Cellular Cures Duke University Durham NC USA.
Laura A ValenteMarcus Center for Cellular Cures Duke University Durham NC USA.
Li XuMarcus Center for Cellular Cures Duke University Durham NC USA.
Shane M O'NeilMarcus Center for Cellular Cures Duke University Durham NC USA.
Lauren R BeggMarcus Center for Cellular Cures Duke University Durham NC USA.
Joanne KurtzbergMarcus Center for Cellular Cures Duke University Durham NC USA.
Anthony J FilianoMarcus Center for Cellular Cures Duke University Durham NC USA.ORCID https://orcid.org/0000-0003-4329-0151
Duke University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Thymus implantation is a recently FDA-approved therapy for congenital athymia. Patients receiving thymus implantation develop a functional but incomplete T cell compartment. Our objective was to develop a mouse model to study clinical thymus implantation in congenital athymia and to optimise implantation procedures to maximise T cell education and expansion of naïve T cells. Methods: Using Results: We determined that thymus implants in Conclusion: We conclude that implanting cultured thymus into the muscle of

Indexed as

primary immunodeficiency disordersT cellsthymustranslational immunologytransplant immunology

Identifiers

PMID38020730
PMCPMC10665642
OpenAlexW4388991432

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.